Video

Data Diversity Initiative: Tackling the Medical Research Data Gap

The data-gap in medical research is well documented, and has serious implications for large sections of the world’s population.

Diseases, treatments and drugs affect people differently according to factors such as race, ethnicity, gender or age, meaning these data gaps in research drastically limit our knowledge to effectively diagnose and treat disease. In the age of digital health, the data-gap can no longer be overlooked if we are to avoid exacerbating existing health inequalities.  

At BenevolentAI, we launched an internal initiative to address this challenge, raise awareness and brainstorm possible solutions to the data diversity problem. We then broadened our scope by engaging with the wider scientific and research community.  

During our inaugural event, we invited a panel of experts to discuss the problem of diversity in medical data, and then invited our audience to participate in an interactive workshop to brainstorm holistic and concrete solutions:  

  • Maria Nelson, Senior Head of Innovation Practice, Digital Catapult  
  • Jackie Hunter, CE Clinical and Strategic Partnerships BenevolentAI  
  • Rob Wilson, Senior Regulatory Consultant, DLRC  
  • Diane Harbison, CEO Decipher Analytics  
  • Dawn Duhaney, Product Manager, Wellcome Trust


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021